<a href="https://www.fiercebiotech.com/biotech/caribou-boosts-case-shelf-car-t-matches-autologous-drugs-ahead-phase-3" hreflang="en">Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3</a>
Caribou Biosciences has reported that its allogeneic CAR-T therapy, vispacabtagene regedleucel (vispa-cel), achieved a median progression-free survival of 17.1 months in lymphoma patients, outperforming existing autologous therapies like Breyanzi and Yescarta. Despite the promising results, the company faces challenges in securing investor support and funding for its upcoming phase 3 trial targeting patients who are ineligible for traditional autologous treatments.
Caribou Biosciences' allogeneic CAR-T cell therapy candidate, vispa-cel, has shown promising median progression-free survival (PFS) of 17.1 months, surpassing the PFS of approved autologous therapies such as Breyanzi and Yescarta. This positions vispa-cel as a competitive off-the-shelf alternative, particularly for patients ineligible for or unable to access autologous treatments. Despite strong clinical results, Caribou faces financial challenges, highlighting a potential opportunity for investment or strategic partnerships to support their upcoming phase 3 trial and market expansion efforts.